Globus Medical, Inc. (GMED)

Market Cap	10.00B +28.0%
Revenue (ttm)	3.14B +19.7%
Net Income	535.43M +50.1%
EPS	3.91 +51.9%
Shares Out	134.26M
PE Ratio	19.03
Forward PE	14.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	471,354
Open	73.94
Previous Close	74.16
Day's Range	73.54 - 74.83
52-Week Range	54.15 - 101.40
Beta	0.96
Analysts	Buy
Price Target	103.23 (+38.56%)
Earnings Date	Nov 5, 2026

About GMED

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractu...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Aug 3, 2012
• Employees: 6,000
• Stock Exchange: NYSE
• Ticker Symbol: GMED
• Website: https://www.globusmedical.com

Financial Performance

In 2025, Globus Medical's revenue was $2.94 billion, an increase of 16.65% compared to the previous year's $2.52 billion. Earnings were $537.87 million, an increase of 422.28%.

Analyst Summary

According to 15 analysts, the average rating for GMED stock is "Buy." The 12-month stock price target is $103.23, which is an increase of 38.56% from the latest price.

Price Target

$103.23

(38.56% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 18, 2026

Data Sources Report a data error